Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology
NEW YORK , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced four poster presentations at the 56th Annual Meeting of the American College
View HTML
Toggle Summary Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference
NEW YORK , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates , Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia
NEW YORK , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track
View HTML
Toggle Summary Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting
NEW YORK , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced poster presentations related to its lumateperone and ITI-214 development
View HTML
Toggle Summary Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer
NEW YORK , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced that Andrew Satlin M.D . has joined the company as Executive Vice President and
View HTML
Toggle Summary Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update
NEW YORK , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September 30, 2017 , and
View HTML
Toggle Summary Intra-Cellular Therapies to Host Third Quarter 2017 Financial Results Conference Call and Webcast
NEW YORK , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that the underwriters of its previously announced underwritten public offering of 9,677,419 shares of its common stock at a public offering price of $15.50 per
View HTML
Toggle Summary Intra-Cellular Therapies Announces Commencement of Enrollment of a Clinical Trial Evaluating ITI-214 in Patients with Parkinson's Disease
NEW YORK, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the Company has commenced enrollment in the ITI-214-105 Phase 1/2 clinical
View HTML
Toggle Summary Intra-Cellular Therapies Announces Closing of $150 Million Public Offering of Common Stock
NEW YORK, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,677,419 shares of its common stock at a public offering price of $15.50 per share.
View HTML
Toggle Summary Intra-Cellular Therapies Prices $150 Million Public Offering of Common Stock
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 9,677,419 shares of its common stock at a public offering price of $15.50 per share.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies
View HTML
Toggle Summary Intra-Cellular Therapies to Participate at Upcoming Investor Conferences
NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced it will participate at the following investor conferences in September
View HTML
Toggle Summary Intra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia
Intra-Cellular Therapies to Host a Conference Call Today at 8:30 a.m. ET NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced
View HTML
Toggle Summary Intra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia Program
Following FDA interactions Company moving forward with long-term safety study of lumateperone and preparing for NDA submission for the treatment of schizophrenia by mid-2018
View HTML